Share Twitter LinkedIn Facebook Email Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains how CDK 4/6 inhibitors are being integrated into breast cancer treatment.
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read